If you are looking for an answer to the question What is Artificial Intelligence? and you only have a minute, then here's the definition the Association for the Advancement of Artificial Intelligence offers on its home page: "the scientific understanding of the mechanisms underlying thought and intelligent behavior and their embodiment in machines."
However, if you are fortunate enough to have more than a minute, then please get ready to embark upon an exciting journey exploring AI (but beware, it could last a lifetime) …
The Alphabet subsidiary is partnering with a UK hospital to test whether its algorithm can help diagnose diabetic retinopathy and age-related macular degeneration sooner. Diabetic retinopathy and age-related macular degeneration are serious conditions that can lead to loss of eyesight, and they affect more than 100 million people across the globe. The good news is that early detection can minimize the damage, but the bad news is that diagnosis can often take time. Now, Google DeepMind, a subsidiary of Google parent company Alphabet Inc., hopes to speed up the process by applying artificial intelligence. Optical coherence tomography, a noninvasive imaging technique that can produce 3-D scans of the eye, as well as digital scans of the back of the eye can be used to diagnose both diabetic retinopathy and age-related macular degeneration.
Scientists in the Netherlands are looking to pair artificial intelligence (AI), or machine learning, with MRI techniques that measure blood perfusion in the brain. This approach, said the researchers -- diagnoses early forms of dementia and predicts the onset of Alzheimer's disease with between 82 and 90 percent accuracy. Though there is no cure for Alzheimer's, experts believe that early diagnosis could improve patient outcomes and alleviate the healthcare system's financial burden associated with the disease. According to the Alzheimer's Association, only 45 percent of patients and their caregivers dealing with the disease are aware of the diagnosis. Recent Alzheimer's research suggests that it may be possible to isolate biomarkers in the blood to diagnose the disease, demonstrated by scientists at Rowan University.
IBM announced a deal with sports and fitness retailer Under Armour Inc. to use machine learning technology from Watson and showed off an application for diabetic care developed with the supercomputer's data, highlighting the company's effort to expand Watson's capabilities for the health-care industry. IBM and Under Armour released an updated fitness application for Apple Inc.'s iPhones that uses data powered by Watson, IBM Chief Executive Officer Ginni Rometty said Wednesday in a speech at the International Consumer Electronics Show in Las Vegas. Separately, Medtronic Plc CEO Omar Ishrak joined Rometty on stage to unveil a prototype for a diabetes-management app that tests have shown may be capable of predicting hypoglycemic events as early as three hours in advance. The application still needs to go through regulatory review -- it will roll out this summer, Rometty said. The ability to predict the hypoglycemic events is a "breakthrough," she said.
Emerald Medical Applications Corp. (OTCQB: MRLA), an Israeli-based company engaged in the development and sale of its proprietary DermaCompare cloud-based, artificial intelligence technology for the early diagnosis of Melanoma/skin cancer, today announced entry into a cooperation agreement with Terem, one of Israel's largest community-based, emergency healthcare providers with 17 medical facilities, serving over 700,000 patients throughout Israel. Starting in April 2016, Emerald will begin to offer its DermaCompare technology at each of Terem's clinics throughout Israel, offering advanced dermatological examinations, diagnosisand treatment led by a leading professional Dermatologists. DermaCompare is Emerald's cloud-based, artificial, intelligence technology using Total Body Photography imaging which is capable of being automatically compared to a patient's previous images to diagnose and detect the presence of Melanoma in its earliest stages. Lior Wayn, Emerald's CEO, stated that "DermaCompare, Emerald's FDA approved, HIPPA compliant software technology, which can be downloaded from any Mac or Android based App store, enables physicians andtheir patients, using virtually any digital camera, including cell phones, iPads, tablets and other similar devices, to take Total Body Photography images and, in real-time, transmit these images for dermatological evaluation and identification of suspicious moles, lesions and other skin conditions. These images are then compared using Emerald's cloud database, as well as the patients previous Total Body Photography images, which will dramatically enhance a physician's ability to detect Melanoma earlier, more accurately and more efficient than other means of diagnosis."
Cisco is working with Berlin's government officials to push forward plans in making the city smarter. The San Jose, California-based IT firm announced plans last week to work with Berlin's Senate Department of Economics, Technology and Research in digitizing the lives of Berlin's residents. In a statement, the company said telemedicine -- remote communication and the diagnosis of patients across digital platforms -- security and network infrastructure improvements are the main areas of focus. Cornelia Yzer, Senator for Economics, Technology, and Research in Berlin, and Anil Menon, the Global President of Smart Connected Communities, joined with Cisco to sign a Memorandum of Understanding, leading to the investment as part of Cisco's 500 million "Deutschland Digital" initiative. The "Deutschland Digital" program, announced in March this year, is Cisco's answer to accelerating the country's digitization.